- জেনেরিক নাম
- Nilotinib
- শক্তি
- 200 mg
- ডোজ ফর্ম
- Capsule
- প্রস্তুতকারক
- Renata PLC.
৳ ৭৮৪ ৳ ৮০০ ২% ছাড় প্রতি ইউনিট
দাম হালনাগাদ: ১৬ Nov ২০২৬
NILOREN CAPSULE হলো Nilotinib-এর একটি ব্র্যান্ড, শক্তি ২০০ mg, ক্যাপসুল আকারে। NILOREN CAPSULE-এর প্রতি ইউনিটের দাম ৮০০ টাকা। এই ব্র্যান্ডের প্রস্তুতকারক Renata PLC। NILOREN CAPSULE-এর সাথে Nilotinib-এর অন্য ব্র্যান্ডের দাম নিচে তুলনা করে দেখুন। এই তথ্য শুধু জানার জন্য; ঔষধ সবসময় ডাক্তারের পরামর্শ অনুযায়ী খাবেন, মাত্রা বা ব্র্যান্ড নিয়ে প্রশ্ন থাকলে ফার্মাসিস্টকে জিজ্ঞেস করুন।
NILOREN CAPSULE is a targeted cancer medicine containing nilotinib. It belongs to a group of drugs that interfere with specific molecules involved in cancer cell growth and survival. This type of medicine is used in adults for certain advanced cancers after prior chemotherapy. The capsule is taken by mouth, but the exact dose and schedule are set by the doctor based on the individual case. Nilotinib is not a general cancer treatment and is not suitable for everyone. It requires careful medical supervision, and patients should discuss all risks and benefits with their doctor.
NILOREN CAPSULE is used for advanced renal cell carcinoma and advanced soft tissue sarcoma in patients who have already received chemotherapy. It is not shown to be effective for adipocytic soft tissue sarcoma or gastrointestinal stromal tumors. The doctor decides if this medicine is appropriate based on the specific type and stage of cancer.
Take NILOREN CAPSULE exactly as prescribed by your doctor. Swallow the capsule whole with water; do not crush or chew it. The doctor will determine the dose and how often you take it. Do not change the dose or stop treatment without consulting your doctor. If you miss a dose, ask your doctor or pharmacist for advice.
Common side effects include rash, itching, headache, fever, fatigue, nausea, constipation, diarrhoea, hair loss, muscle spasms, joint or muscle pain, swelling, and dizziness. Serious side effects can occur, such as liver problems, heart rhythm changes, high blood pressure, bleeding, and low blood cell counts. Tell your doctor promptly if you notice any unusual symptoms.
NILOREN CAPSULE can harm an unborn baby. Women who can become pregnant should use effective contraception during treatment and for a period after, as advised by their doctor. Do not breastfeed during treatment and for some time after the last dose. Tell your doctor if you are pregnant, planning pregnancy, or breastfeeding. Patients with liver problems, heart rhythm disorders, or those taking certain other medicines should ask the doctor first. Older adults may have a higher risk of liver toxicity. Always inform your doctor of all medicines you take.
No, it can cause fetal harm. Pregnant women should be aware of the risk to the fetus. Do not breastfeed during treatment and for a period after the final dose. Discuss contraception and breastfeeding with your doctor.
NILOREN CAPSULE is a targeted cancer therapy containing nilotinib. It is used for advanced renal cell carcinoma and advanced soft tissue sarcoma after prior chemotherapy. It is not effective for certain other soft tissue sarcomas.
People with known hypersensitivity to nilotinib or any ingredient should avoid it. Those with liver problems, heart rhythm disorders, or taking certain other medicines should ask the doctor first. Older adults may be at higher risk of liver toxicity.
No, swallow the capsule whole with water. Crushing or chewing may affect how the medicine is absorbed. If you have trouble swallowing, ask your doctor or pharmacist for guidance.
৳ ৭৮৪ ৳ ৮০০ ২% ছাড় প্রতি ইউনিট
দাম হালনাগাদ: ১৬ Nov ২০২৬
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Nilotinib is indicated in advanced renal cell carcinoma (RCC), advanced soft tissue sarcoma (STS) who have received prior chemotherapy. The efficacy of Nilotinib 200 for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors has not been demonstrated.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T- cell kinase (Itk), lymphocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro, Pazopanib inhibited ligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR receptors.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
The recommended starting dose of Pazopanib is 800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal). The dose of Pazopanib should not exceed 800 mg. Tablets should not be crushed due to the potential for an increased rate of absorption which may affect systemic exposure. If a dose is missed, it should not be taken if it is less than 12 hours until the next dose or as directed by the registered physicians.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes: In vitro studies suggested that the oxidative metabolism of Pazopanib in human liver microsomes is mediated primarily by CYP3A4, with minor contributions from CYP1A2 and CYP2C8. Therefore, inhibitors and inducers of CYP3A4 may alter the metabolism of Pazopanib.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
It is contraindicated in patients with known hypersensitivity to Pazopanib or any other components of this product.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Rash, pruritus, hepatotoxicity, headache, fever, fatigue, GI disturbances (nausea, constipation, diarrhoea), alopecia, asthenia, muscle spasms, arthralgia, myalgia, pain (e.g. musculoskeletal or chest pain), oedema, folliculitis, papilloma, insomnia, dizziness, vertigo, anxiety, paraesthesia, hyperhidrosis, dry skin, urticaria, acne, conjunctivitis, dry eye, flushing, dyspnoea, cough, myelosuppression (e.g. thrombocytopenia, neutropenia, and anaemia), thrombotic disorders or haemorrhage, arrhythmias, heart failure, pericarditis, palpitations, HTN, angina, MI; elevated AST/ALT, serum lipase; electrolyte imbalances.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Pazopanib can cause fetal harm when administered to a pregnant woman. There are no available data in pregnant women to inform a drug-associated risk. Pregnant women or women should be advised of the childbearing potential of the risk to a fetus. There is no information regarding the presence of Pazopanib or its metabolites in human milk, or their effects on the breastfed infant, or on milk production. Because of the potential for serious adverse reactions in breastfed infants from Pazopanib, a lactating woman should be advised not to breastfeed during treatment with Pazopanib and for 2 weeks after the final dose.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Hepatic Toxicity and Hepatic Impairment: In clinical trials with Pazopanib, hepatotoxicity, manifested as increases in serum transaminases (alanine transferase [ALT], aspartate aminotransferase [AST]) and bilirubin, was observed. This hepatotoxicity can be severe and fatal. Patients older than 65 years are at greater risk for hepatotoxicity. Transaminase elevations occur early in the course of treatment (92.5% of all transaminase elevations of any grade occurred in the first 18 weeks).এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Pazopanib doses up to 2000 mg have been evaluated in clinical trials. Dose-limiting toxicity (Grade 3 fatigue) and Grade 3 hypertension were each observed in 1 of 3 patients dosed at 2000 mg daily and 1000 mg daily, respectively. Treatment of overdose with Nilotinib should consist of general supportive measures. There is no specific antidote for overdosage of Nilotinib. Hemodialysis is not expected to enhance the elimination of Nilotinib because Pazopanib is not significantly renally excreted and is highly bound to plasma proteins.এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Store in a cool (not above 30°C) and dry place, away from sunlight. Keep out of reach of children.ঔষধের তথ্য শুধু জানার জন্য, এটি চিকিৎসা পরামর্শ নয়। সবসময় ডাক্তারের প্রেসক্রিপশন মানুন এবং ফার্মাসিস্টের সাথে কথা বলুন।